Chemical inhibitors of GPR89 include a range of compounds that inhibit various ion channels and transporters, which are critical for the function of this protein in maintaining cellular ion homeostasis. Amiloride, for example, is known to inhibit sodium channels, directly impacting the ion transport system with which GPR89 is associated. By reducing the activity of these channels, GPR89's ability to regulate ion transport is functionally inhibited. Similarly, Benzamil, another sodium channel blocker, can decrease the ion exchange capabilities that GPR89 influences, leading to a dampening of its cellular ion regulation role. The action of Hexamethonium as a nicotinic acetylcholine receptor antagonist can also indirectly inhibit GPR89's function, given that GPR89 is implicated in ion channel regulation. Blockage of these receptors by Hexamethonium can, therefore, affect the ion channel activities that GPR89 is known to modulate.
Further, Trimethadione, an oxazolidinedione, may alter ion channel function, thus potentially inhibiting GPR89's regulatory effects on these channels. Quinine, a voltage-gated ion channel blocker, can inhibit the electrical signals that GPR89 is responsive to, thereby inhibiting its role in ionic signal transduction. Loop diuretics like Bumetanide and Furosemide, which inhibit the Na-K-Cl cotransporter, could also impact the ionic environment that GPR89 regulates, leading to an inhibition of its function. Agents like Clofilium, which inhibits potassium channels, and Indapamide, which affects ion transport pathways, can further inhibit the GPR89-mediated ion homeostasis. Additionally, Hydrochlorothiazide, by inhibiting sodium chloride transporters, can lead to an inhibition of GPR89's function if it is involved in similar ion transport pathways. Triamterene, a direct inhibitor of epithelial sodium channels, can inhibit GPR89's activity in sodium transport regulation. Lastly, Spironolactone, by antagonizing aldosterone receptors, can indirectly influence the ionic gradients that GPR89 regulates, thereby inhibiting its functional role in ion transport. All these chemicals demonstrate the diverse ways by which GPR89's function in cellular ion regulation can be inhibited, emphasizing the protein's central role in maintaining the delicate balance of ions within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride inhibits sodium channels which are part of the ion transport system that GPR89 is associated with, leading to reduced activity of GPR89 in ion transport regulation. | ||||||
Benzamil•HCl | 161804-20-2 | sc-201070 | 50 mg | $195.00 | 1 | |
Benzamil blocks epithelial sodium channels, and by doing so, it can decrease the ion exchange influenced by GPR89, functionally inhibiting its role in cellular ion homeostasis. | ||||||
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $79.00 $104.00 $166.00 $354.00 $572.00 | 1 | |
Quinine, known for its ability to block voltage-gated ion channels, can dampen the electrical signals that GPR89 responds to, thus inhibiting its activity in ionic signal transduction. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $109.00 $228.00 | 9 | |
Bumetanide inhibits Na-K-Cl cotransporter, which could impact the ionic environment that GPR89 is known to help regulate, thereby inhibiting its function. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
Furosemide inhibits Na-K-Cl cotransporter, similar to Bumetanide, potentially reducing GPR89 activity by altering the ion gradient it may regulate. | ||||||
Clofilium tosylate | 92953-10-1 | sc-391228 sc-391228A | 25 mg 100 mg | $437.00 $1040.00 | 1 | |
Clofilium inhibits potassium channels, which can subsequently inhibit the regulatory function of GPR89 in maintaining potassium ion homeostasis. | ||||||
Indapamide | 26807-65-8 | sc-204777 sc-204777A | 250 mg 1 g | $46.00 $64.00 | ||
Indapamide, while primarily a diuretic, can affect ion transport pathways that GPR89 is involved with, leading to an inhibition of its function in ion regulation. | ||||||
Hydrochlorothiazide | 58-93-5 | sc-207738 sc-207738A sc-207738B sc-207738C sc-207738D | 5 g 25 g 50 g 100 g 250 g | $55.00 $240.00 $333.00 $562.00 $988.00 | ||
Hydrochlorothiazide inhibits sodium chloride transporters, which could lead to a functional inhibition of GPR89 if it is involved in the same ionic regulatory pathways. | ||||||
Triamterene | 396-01-0 | sc-213103A sc-213103 | 1 g 5 g | $22.00 $54.00 | ||
Triamterene directly blocks epithelial sodium channels and can thus inhibit the activity of GPR89 if it is functionally related to sodium transport regulation. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone antagonizes aldosterone receptors, which indirectly could inhibit GPR89's presumed role in ion transport by influencing the ionic gradients it regulates. | ||||||